Don’t Fall Under Pressure: Spontaneous Intracerebral Hemorrhage Management Updates
While spontaneous intracerebral hemorrhage (sICH) is not as common as ischemic stroke, prompt diagnosis and management of sICH is essential to improve patient outcomes. The American Heart Association released new guidelines in 2022 for the management of this condition. Referring to these updates, the session will provide pharmacists with updated, evidence-based recommendations to improve practice and patient care in those with sICH. This presentation will cover background information on sICH, blood pressure control, anticoagulant reversal, and the types of supportive care required for these patients.
Learning Outcomes
At the completion of this activity, the participant should be able to:
- Review the pathophysiology, presentation, and diagnosis of spontaneous intracerebral hemorrhage (sICH)
- Explain guideline recommended management of blood pressure and anticoagulant reversal in patients with sICH
- Describe supportive care measures in patients with sICH
- Identify secondary prevention measures in patients with sICH
Presenter
Emily Duff, PharmD, is a PGY2 Critical Care Pharmacy Resident at Baystate Medical Center. She earned her PharmD from the University of Rhode Island in 2021. Her primary interest areas include medical intensive care, emergency medicine, and academia.
Course Fee: Free for MCPHS alumni, full-time staff, and for all other professionals.
Release Date: June 7, 2023
Expiration Date: June 7, 2024
ACPE UAN: 0026-0000-23-012-H01-P | Knowledge
ACPE Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1.0 (0.1 CEU)
After registering or logging into mcphsce.org, you can view CE modules in our library.
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MCPHS designates this educational activity for a total of 1.0 contact hours (0.1 CEUs).
To receive credit, participants must complete pre and post-assessments, view the entire presentation, and evaluate the session. Participant credit will be reported to the CPE Monitor upon conclusion. Transcripts may be printed from the CPE Monitor.
The policy of Massachusetts College of Pharmacy and Health Sciences is ensuring balance, independence, objectivity, and scientific rigor in all of its educational activities. Any individuals involved in planning or content creation for a continuing education activity are required to disclose financial relationships with ineligible companies that have occurred within the last 24 months. The intent of the policy is to identify and mitigate potential conflicts of interest that may affect the activity. All clinical medicine recommendations must be based on evidence accepted within the medical profession.
Emily Duff, PharmD, does not hold relevant financial relationships with ineligible companies. She will discuss off-label usage of 4-factor prothrombin complex concentrate, protamine, desmopressin, recombinant factor VIIa, and tranexamic acid.
Content reviewer Scott May, PharmD, BCCCP, does not hold relevant financial relationships with ineligible companies.
Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies related to the content of this presentation.
Massachusetts College of Pharmacy and Health Sciences will identify, review, and mitigate all conflicts of interest disclosed prior to delivery of an educational activity to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but provides participants with information that may be of potential importance when they are evaluating content.